Obesity, Metabolic Syndrome, Diabetes and Kidney Stones: Strengthening Links Over Time?

gov identifier: NCT03093103 ) analysis conducted in healthy/overweight nondiabetic volunteers without kidney stones, empagliflozin lowered day- and night-time urine pH while increasing urinary citrate by ~50%; urinary NH 3 decreased only numerically and did not reach statistical significance, so reduced ammoniagenesis remains hypothesis-generating in this setting. 79 In Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers (SWEETSTONE; ClinicalTrials. gov identifier: NCT04911660 ), a double-blind, placebo-controlled crossover phase II trial in

also in 111,027 other papers